A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis

Journal of Cystic Fibrosis

Volumn 13, Issue 2, 2014, Pages 148-155

  Konstan, M W ^a,f   Doring G ^b   Heltshe, S L ^c   Lands, L C ^d   Hilliard, K A ^f   Koker, P ^e   Bhattacharya, S ^e   Staab, A ^f   Hamilton, A ^g  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

^e RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f Boehringer Ingelheim ^*  (Canada)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Anti inflammatory therapy; Clinical trial; Cystic fibrosis; Leukotriene B4 receptor antagonist; Lung disease

Indexed keywords

AMELUBANT; AMIDINE; ANTIINFLAMMATORY AGENT; CARBAMIC ACID DERIVATIVE; LEUKOTRIENE B4 RECEPTOR;

ADOLESCENT; ADULT; ANTAGONISTS AND INHIBITORS; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; DRUG MONITORING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EARLY TERMINATION OF CLINICAL TRIAL; FEMALE; HUMAN; INFLAMMATION; LUNG FUNCTION TEST; LUNG LAVAGE; MALE; METABOLISM; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SPUTUM; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AMIDINES; ANTI-INFLAMMATORY AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CARBAMATES; CHILD; CYSTIC FIBROSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG MONITORING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; HUMANS; INFLAMMATION; MALE; RECEPTORS, LEUKOTRIENE B4; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SPUTUM; TREATMENT OUTCOME;

EID: 84895069337     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2013.12.009     Document Type: Article

References (37)

1. Cantin A. Cystic fibrosis lung inflammation: early, sustained, and severe. Am J Respir Crit Care Med 1995, 151:939-941.
2. Konstan M.W., Berger M. Current understanding of the inflammatory process in cystic fibrosis - onset and etiology. Pediatr Pulmonol 1997, 24:137-142.
3. Döring G., Ratjen F. Immunology of Cystic Fibrosis. Cystic Fibrosis 2007, 69-80. Arnold Hammer, London, England. M.E. Hodson, D. Geddes, A. Bush (Eds.).
4. Döring G., Conway S.P., Heijerman H.G., Hodson M.E., Hoiby N., Smyth A., et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000, 16:749-767.
5. Konstan M.W. Therapies aimed at airway inflammation in cystic fibrosis. Clinics in Chest Medicine: Cystic Fibrosis 1998, 19:505-513. W.B. Saunders Co., Philadelphia. S.B. Fiel (Ed.).
6. Döring G., Hoiby N., for the Consensus Study Group Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004, 3:67-91.
7. Chmiel J.F., Konstan M.W. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med 2007, 28(2):331-346.
8. Konstan M.W., Byard P.J., Hoppel C.L., Davis P.B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995, 332:848-854.
9. Lands L.C., Milner R., Cantin A.M., Manson D., Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007, 151:249-254.
10. 1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007, 176:1084-1089.
11. Konstan M.W. Ibuprofen therapy for cystic fibrosis lung disease: revisited. Curr Opin Pulm Med Nov 2008, 14(6):567-573. [Review].
12. Bergmann U., Scheffer J., Koller M., Schonfeld W., Erbs G., Muller F.E., et al. Induction of inflammatory mediators (histamine and leukotrienes) from rat peritoneal mast cells and human granulocytes by Pseudomonas aeruginosa strains from burn patients. Infect Immun 1989, 57:2187-2195.
13. Ford-Hutchinson A.W., Bray M.A., Doig M.V., Shipley M.E., Smith M.J. Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 1980, 286:264-265.
14. Cromwell O., Walport M.J., Taylor G.W., Morris H.R., O'Driscoll B.R., Kay A.B. Identification of leukotrienes in the sputum of patients with cystic fibrosis. Adv Prostaglandin Thromboxane Leukot Res 1982, 9:251-257.
15. 4 is markedly elevated in epithelial lining fluid of patients with cystic fibrosis. Am Rev Respir Dis 1993, 148:896-901.
16. Greally P., Hussein M.J., Cook A.J., Sampson A.P., Piper P.J., Price J.F. Sputum tumor necrosis factor-alpha and leukotriene concentrations in cystic fibrosis. Arch Dis Child 1993, 68:389-392.
17. 4. Lancet Aug 21 1993, 342(8869):465-469.
18. 4 receptor antagonist. J Pharmacol Exp Ther 2001, 297(1):458-466.
19. 4 receptor antagonist, in adult and pediatric CF patients. Pediatr Pulmonol 2003, (Suppl. 25):258-259. [abstract].
20. 4 receptor antagonist, in adult and pediatric CF patients. Pediatr Pulmonol 2003, (Suppl. 25):259. [abstract].
21. 4 antagonist) for the treatment of CF lung disease. Pediatr Pulmonol 2005, (Suppl. 28):125. [abstract].
22. American Thoracic Society Standardization of spirometry - 1994 update. Am J Respir Crit Care Med 1995, 152:1107-1136.
23. Wang X., Dockery D.W., Wypij D., Fay M.E., Ferris B.G. Pulmonary function between 6 and 18years of age. Pediatr Pulmonol 1993, 15:75-88.
24. Knudson R.J., Lebowitz M.D., Holberg C.J., Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis 1983, 127:725-734.
25. Fuchs H.J., Borowitz D.S., Christiansen D.H., Morris E.M., Nash M.L., Ramsey B.W., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994, 331:637-642.
26. Lymp J., Hilliard K., Rosenfeld M., Koker P., Hamilton A., Konstan M. Pulmonary exacerbations in a phase 2 clinical trial of BIIL284BS in CF: development and implementation of a respiratory and systemic symptoms questionnaire (RSSQ). Pediatr Pulmonol 2009, (Suppl. 32):288.
27. Spencer D.A., Sampson A.P., Green C.P., Costello J.F., Piper P.J., Price J.F. Sputum cysteinyl-leukotriene levels correlate with severity of pulmonary disease in children with cystic fibrosis. Pediatr Pulmonol 1992, 12:90-94.
28. Zakrzewski J.T., Barnes N.C., Piper P.J., Costello J.F. Detection of sputum eicosanoids in cystic fibrosis and in normal saliva by bioassay and radioimmunoassay. Br J Clin Pharmacol 1987, 23:19-27.
29. Csoma Z., Kharitonov S.A., Balint B., Bush A., Wilson N.M., Barnes P.J. Increased leukotrienes in exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med 2002, 166:1345-1349.
30. 4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol 1989, 84:19-26.
31. 4. Gut 1996, 39:248-254.
32. 4 and immunological parameters in rheumatoid synovial fluids. Inflammation 1991, 15:497-503.
33. 4 plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci U S A 1995, 92:517-521.
34. Konstan M.W., Vargo K.M., Davis P.B. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. Implications for antiinflammatory therapy in cystic fibrosis. Am Rev Respir Dis Jan 1990, 141(1):186-192.
35. 4 receptor antagonist, in patients with rheumatoid arthritis. Ann Rheum Dis 2004, 63:170-176.
36. 4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66:628-632.
37. Schmitt-Grohé S., Zielen S. Leukotriene receptor antagonists in children with cystic fibrosis lung disease: anti-inflammatory and clinical effects. Paediatr Drugs 2005, 7(6):353-363.